ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) FY2026 Q2 Balance Sheet

Income StatementCash FlowBalance Sheet

Balance Sheet

As of 2026-06-30

Swipe to see the full flow
ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) FY2026 Q2 Balance SheetBalance sheet as of 2026-06-30. The chart shows assets, liabilities and equity at that date.Current liabilities$160.34 MLiabilities$267.96 MNon-current liabilities$107.62 MEquity$220.58 MGross equity(calculated)$1.36 BCurrent assets$467.67 MAssets$488.54 MNon-current assets$20.87 MHOLDINGSASSET CLASSASSETSCLAIM CLASSCLAIM SUB-CLASSCLAIMSMarketable securitiesTrade receivables, netInventoryPrepaid expenses and other current assetsCash and cash equivalentsRestricted cashIntangible assets, netOperating lease right-of-use assetOther assetsProperty, plant, and equipment, netAccrued and other current liabilitiesCurrent portion of long-term debt, netAccounts payableLong-term debt, netOperating lease liability, long-termOther long-term liabilitiesAdditional paid-in capitalCommon stock, $0.0001 par value; 300,000 shares authorized at June 30, 2026 and December 31, 2025; 125,591 and 123,333 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectivelyCurrent assetsNon-current assetsAssetsCurrent liabilitiesNon-current liabilitiesLiabilitiesEquityGross equity (calculated)Accumulated deficitAccumulated other comprehensive income (loss)Current liabilitiesCurrent liabilities$160.34 MAccrued and other current liabilitiesAccrued and other current liabilities$146.79 MLiabilitiesLiabilities$267.96 MCurrent portion of long-term debt, netCurrent portion of long-term debt, net$6.95 MAccounts payableAccounts payable$6.60 MNon-current liabilitiesNon-current liabilities$107.62 MLong-term debt, netLong-term debt, net$101.95 MEquityEquity$220.58 MOperating lease liability, long-termOperating lease liability, long-term$5.24 MOther long-term liabilitiesOther long-term liabilities$431.00 KGross equity (calculated)Gross equity(calculated)$1.36 BCurrent assetsCurrent assets$467.67 MMarketable securitiesMarketable securities$204.43 MAssetsAssets$488.54 MTrade receivables, netTrade receivables, net$155.16 MInventoryInventory$38.88 MPrepaid expenses and other current assetsPrepaid expenses and other current assets$34.77 MCash and cash equivalentsCash and cash equivalents$34.12 MRestricted cashRestricted cash$308.00 KIntangible assets, netIntangible assets, net$13.69 MAdditional paid-in capitalAdditional paid-in capital$1.36 BNon-current assetsNon-current assets$20.87 MOperating lease right-of-use assetOperating lease right-of-use asset$4.25 MOther assetsOther assets$2.05 MProperty, plant, and equipment, netProperty, plant, and equipment, net$872.00 KCommon stock, $0.0001 par value; 300,000 shares authorized at June 30, 2026 and December 31, 2025; 125,591 and 123,333 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectivelyCommon stock$12.00 KAccumulated deficitAccumulated deficit−$1.13 BAccumulated other comprehensive income (loss)Accumulated other comprehensive income (loss)−$656.00 K
Chart details

ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) FY2026 Q2 Balance Sheet

Balance sheet as of 2026-06-30. The chart shows assets, liabilities and equity at that date.

Assets
488,537,000 US dollars
Current assets
467,671,000 US dollars
Non-current assets
20,866,000 US dollars
Liabilities
267,958,000 US dollars
Current liabilities
160,340,000 US dollars
Non-current liabilities
107,618,000 US dollars
Equity
220,579,000 US dollars
Marketable securities
204,431,000 US dollars
Trade receivables, net
155,162,000 US dollars
Inventory
38,879,000 US dollars
Prepaid expenses and other current assets
34,770,000 US dollars
Cash and cash equivalents
34,121,000 US dollars
Restricted cash
308,000 US dollars
Intangible assets, net
13,687,000 US dollars
Operating lease right-of-use asset
4,253,000 US dollars
Other assets
2,054,000 US dollars
Property, plant, and equipment, net
872,000 US dollars
Accrued and other current liabilities
146,786,000 US dollars
Current portion of long-term debt, net
6,950,000 US dollars
Accounts payable
6,604,000 US dollars
Long-term debt, net
101,950,000 US dollars
Operating lease liability, long-term
5,237,000 US dollars
Other long-term liabilities
431,000 US dollars
Additional paid-in capital
1,355,593,000 US dollars
Common stock, $0.0001 par value; 300,000 shares authorized at June 30, 2026 and December 31, 2025; 125,591 and 123,333 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively
12,000 US dollars
Accumulated deficit
negative 1,134,370,000 US dollars
Accumulated other comprehensive income (loss)
negative 656,000 US dollars
Gross equity (calculated)
1,355,605,000 US dollars. Net equity plus the magnitudes of its negative contributions equals gross positive equity. The negative contributions enter this reconciliation as add-backs; their filed signs stay negative.

Chart connections

  • Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
  • Treasury shares and other negative equity contributions reduce equity.
ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) FY2026 Q2 Balance Sheet Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!